Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

GPs told to ignore NICE statin prescribing guidance in cost-cutting drive

Exclusive GPs have been told to ignore current NICE lipid modification guidelines on statin prescribing in low-risk people, under a cost-saving policy at one CCG.

NHS Stockport CCG has advised GPs should only prescribe statins to people if they are found to be at a 20% or greater risk of cardiovascular disease – and not at the lower NICE-recommended threshold of 10%-20%.

The CCG has also stipulated that GPs should prescribe simvastatin first-line rather than the NICE-recommended lipid-lowering drug atorvastatin, as part of measures to control spending.

NICE condemned the decision, which it said meant people were being denied the opportunity to lower their risk of a disease that 'maims and kills one in three'.

The GPC said that the CCG's decision was 'strange' and 'born out of desperation'.

A recent prescribing news bulletin from the CCG said it had 'made the decision not to implement the NICE Lipid Modification Guidelines 2014', adding: ‘We recommend that patients should be treated if their CVD risk is 20% or above and first line treatment should be with simvastatin 40mg.’

The NICE guidelines state that GPs should offer patients the option of a statin if their 10-year risk of cardiovascular disease is 10% or higher and recommend treatment with atorvastatin as the most effective treatment option because it is 'more potent than simvastatin and less likely to interact with other drugs, as well as being easier for patients to take' .

In a statement to Pulse, NHS Stockport CCG said the decision to block the updated NICE guidance was part of a wider strategy to balance finances.

It said: ‘The CCG was required to make some decisions on savings to achieve financial balance and long term financial health. The plan included a decision to not implement the NICE lipid modification guidelines for primary prevention (CG181) in full.

‘There were extensive clinical conversations at the CCG between the guidelines being issued and the decision in March 2015.’

The statement added that GPs should follow NICE advice around lifestyle modifications – such as diet and exercise – in low-risk patients, but that ‘there is a process to follow for clinical exceptionality and this would be the case for patients where lifestyle modification is ineffective or inappropriate’.

Regarding the advice on what lipid-lowering drug, the CCG said: ‘The decision to recommend simvastatin over atorvastatin was made on clinical cost effectiveness grounds.’

Dr Andrew Green, chair of the GPC’s clinical and prescribing subcommittee questioned the CCG’s rationale for controlling statin prescribing and warned GPs must still pay attention to the full NICE guidelines.

Dr Green said: ‘So many CCGs are in deficit due to underfunding, and the pressure on them to achieve financial balance is so great, that we are beginning to see some very strange decisions born out of desperation.’

Dr Green added that 'the difference in price between simvastatin and atorvastatin is so low that it would be very difficult to justify not implementing NICE guidance about choice of statin, and GPs need to remember that they have responsibility for their prescribing decisions’.

Professor Mark Baker, director of the centre for clinical practice at NICE said: 'Cardiovascular disease maims and kills people through coronary heart disease, peripheral arterial disease and stroke. Together, these kill one in three of us.

'This decision amounts to denying patients access to the most effective means of reducing that risk. The overwhelming body of evidence supports the use of statins, even in people at low risk of cardiovascular disease. It clearly shows statins are safe and clinically and cost effective for use in people with a 10% risk of CVD over 10 years.

'Our guidance is intended to prevent many lives being destroyed and it offers a major shift in public health outcomes at relatively low cost. In doing so it places patients, not the cost of treatment, centrally in any decision making about their management.'

The row over the 10% threshold

Simvastatin - Statin - Cardiovascular - Online

Simvastatin - Statin - Cardiovascular - Online

Source: Julian Claxton

NICE's decision to recommend prescribing statins to people at the lower 10% risk threshold led to outcry from GP leaders when the guidelines were updated two years ago.

The GPC was among the dissenters, who warned the recommendation could lead to overmedicalisation and divert GPs' precious resources away from their chronically ill patients onto healthier ‘worried well’ people.

NICE had recommended that GP practices should be incentivised through QOF for statin prescribing at the 10% primary prevention risk threshold in all patients newly diagnosed with diabetes or hypertension.

However, it later rolled back on the recommendation.

 

 

Readers' comments (23)

  • Have already been discussing this with patients.Patients are not keen on statins at the lower risk ranges.At the lower risk ranges I would definitely not take them either.

    Unsuitable or offensive? Report this comment

  • NICE needs more front line GPs on its panels. They currently haven't a clue about GP land.

    Unsuitable or offensive? Report this comment

  • Good for them.

    While I "offer" statins at 10% risk, very few patients take me up on it. This is probably because I word the offer in a way that reflects my own belief that statins at 10% risk are a waste of time.

    Unsuitable or offensive? Report this comment

  • What's the NNT with statins at 10% ?

    Unsuitable or offensive? Report this comment

  • We all know statins at 10% is stupid but to not offer them against NICE guidelines is very risky nowadays. Guidelines ceased to be guidelines long ago and patients will use them to sue you when they have a heart attack or stroke and the CCG is not going to pay your bill.

    Unsuitable or offensive? Report this comment

  • When you do the calculations with patients at 10% risk, most of them feel there is such a tiny benefit to them personally (given that you can't really extrapolate from a population to an individual) that the majority say no.

    Unsuitable or offensive? Report this comment

  • As a patient myself with a cholesterol of 7.7 but a Q-risk less than 10% but a terrible family history my cardiologist is recommending I take a statin but my GP colleagues don't. Whose advice would you take?? Do I wait for the first (and possibly last!) MI or do I start preventative measures now?

    Unsuitable or offensive? Report this comment

  • How safe are NICE Guidlines 50% of clinical trials most of them showing medicines in a negative light arent published or have their end points changed because they are not going to show their original end points in a favourable light as far as drug companies are concerned

    Unsuitable or offensive? Report this comment

  • Re previous comment would the editor/pulse be prepared to seek expert opinion on this and the overall safety of NICE Guidelines based on this fact

    Unsuitable or offensive? Report this comment

  • Cholesterol over 7 I would always reccomend statins whatever the Q risk is

    Unsuitable or offensive? Report this comment

View results 10 results per page20 results per page50 results per page

Have your say